Takip et
christophe massard
christophe massard
Université Paris-Saclay, Faculté de Médecine, Drug Development Department (DITEP), Gustave Roussy
gustaveroussy.fr üzerinde doğrulanmış e-posta adresine sahip - Ana Sayfa
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
JM Michot, C Bigenwald, S Champiat, M Collins, F Carbonnel, ...
European journal of cancer 54, 139-148, 2016
22212016
Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1/PD-L1
S Champiat, L Dercle, S Ammari, C Massard, A Hollebecque, ...
Clinical Cancer Research 23 (8), 1920-1928, 2017
12712017
A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study
R Sun, EJ Limkin, M Vakalopoulou, L Dercle, S Champiat, SR Han, ...
The Lancet Oncology 19 (9), 1180-1191, 2018
10552018
Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study
T Powles, PH O'Donnell, C Massard, HT Arkenau, TW Friedlander, ...
JAMA oncology 3 (9), e172411-e172411, 2017
9352017
Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer
C Massard, MS Gordon, S Sharma, S Rafii, ZA Wainberg, J Luke, ...
Journal of Clinical Oncology 34 (26), 3119-3125, 2016
9272016
High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial
C Massard, S Michiels, C Ferté, MC Le Deley, L Lacroix, A Hollebecque, ...
Cancer discovery 7 (6), 586-595, 2017
7392017
Atezolizumab, an anti–programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study
DF McDermott, JA Sosman, M Sznol, C Massard, MS Gordon, O Hamid, ...
Journal of Clinical Oncology 34 (8), 833-842, 2016
6002016
A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas
F Farace, C Massard, N Vimond, F Drusch, N Jacques, F Billiot, ...
British journal of cancer 105 (6), 847-853, 2011
4842011
Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)
Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ...
Annals of oncology 24 (7), 1807-1812, 2013
4242013
Mutational profile of metastatic breast cancers: a retrospective analysis
C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ...
PLoS medicine 13 (12), e1002201, 2016
3982016
Hyperprogressive disease: recognizing a novel pattern to improve patient management
S Champiat, R Ferrara, C Massard, B Besse, A Marabelle, JC Soria, ...
Nature Reviews Clinical Oncology 15 (12), 748-762, 2018
3872018
VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management
H Izzedine, C Massard, JP Spano, F Goldwasser, D Khayat, JC Soria
European Journal of Cancer 46 (2), 439-448, 2010
3872010
Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study
AR Hansen, C Massard, PA Ott, NB Haas, JS Lopez, S Ejadi, ...
Annals of Oncology 29 (8), 1807-1813, 2018
3642018
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer
A Simonaggio, JM Michot, AL Voisin, J Le Pavec, M Collins, A Lallart, ...
JAMA oncology 5 (9), 1310-1317, 2019
3432019
Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss
JS de Bono, U De Giorgi, DN Rodrigues, C Massard, S Bracarda, A Font, ...
Clinical Cancer Research 25 (3), 928-936, 2019
3142019
Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatin-based first-line chemotherapy
International Prognostic Factors Study Group
Journal of Clinical Oncology 28 (33), 4906-4911, 2010
3092010
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease
FX Danlos, AL Voisin, V Dyevre, JM Michot, E Routier, L Taillade, ...
European Journal of Cancer 91, 21-29, 2018
2942018
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial
C Sweeney, S Bracarda, CN Sternberg, KN Chi, D Olmos, S Sandhu, ...
The Lancet 398 (10295), 131-142, 2021
2712021
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database
A Lorch, C Bascoul-Mollevi, A Kramar, L Einhorn, A Necchi, C Massard, ...
Journal of clinical oncology 29 (16), 2178-2184, 2011
2712011
Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors
J Lewin, JC Soria, A Stathis, JP Delord, S Peters, A Awada, PG Aftimos, ...
Journal of Clinical Oncology 36 (30), 3007-3014, 2018
2692018
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20